Overview
As a committed life-long learner, I am awed by the continued advancements in the field of pediatric transplant and cellular therapy (PTCT). Following completion of my PTCT fellowship training at Duke, I have developed a career dedicated to expanding indications for PTCT and improving associated outcomes. I have a special interest in the mitigation of endotheliopathies and continue to lead global harmonization efforts related to management of toxicities of therapy. As the Division Chief of PTCT at Duke, I am committed to the ensuring our patients receive state of the art care with access to innovative research protocols that change the field. We are committed to training the next generation of physicians in our field with a commitment to global partnerships to improve care for patients across the world.
Current Appointments & Affiliations
Professor of Pediatrics
·
2023 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Chief, Division of Pediatric Transplant & Cellular Therapy
·
2023 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi-Institutional Experience.
Journal Article Pediatr Blood Cancer · October 2025 Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a ... Full text Link to item CiteIntegrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant.
Journal Article JCI Insight · September 9, 2025 Hematopoietic stem cell transplantation (HCT) is a potentially life-saving therapy but can lead to lung injury due to chemoradiation toxicity, infection, and immune dysregulationWe previously showed that bronchoalveolar lavage (BAL) transcriptomes represen ... Full text Link to item CiteAllogeneic Hematopoietic Stem Cell Transplant for an Unknown Inherited Bone Marrow Failure Syndrome With a Novel Compound Heterozygous Mutation.
Journal Article Pediatr Blood Cancer · August 2025 Full text Link to item CiteRecent Grants
A Phase 1/2, Open-Label, Basket Study of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2024 - 2038A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR¿ss+/CD19+ depleted transplantation
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2029Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants with X-Linked Chronic Granulomatous Disease
Clinical TrialPrincipal Investigator · Awarded by Ensoma, Inc. · 2025 - 2027View All Grants
Education, Training & Certifications
St. George's University, School of Medicine (West Indies) ·
2003
M.D.
Adelphi University ·
1999
B.S.